|
Genta Incorporated (Genta), is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company focuses on the identification, development and commercialization of drugs for the treatment of cancer and related diseases. Genta’s research portfolio consists of two major programs: Deoxyribonucleic Acid (DNA)/Ribonucleic Acid (RNA) Medicines and Small Molecules. The DNA/RNA Medicines program includes drugs that are based on using modifications of either DNA or RNA as drugs that can be used to treat disease. This program includes technologies, such as antisense, decoys and small interfering or micro RNAs. Genta’s drug from this program is an investigational antisense compound known as Genasense (oblimersen sodium injection). The Small Molecules program includes drugs, such as Ganite and investigational compounds tesetaxel and G4544.
|
|
Around The Net
You are reading news provided by a variety of web sources.
Drug Pipeline
| Drug Name | Type Of Drug | FDA Status | Drug Phase |
| Tesetaxel |
Cancer
| Fast Track | Phase 2 |
Events
Other:
An inter-subject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors. Poster session at the 2010 Annual ASCO Meeting.
(relates to the drug Tesetaxel)
Add New Event
In order to write a comment you must first login.
Login or Register (for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login or Register (for free!)
Add Link
|
$0.00
1/1/0001 12:00:00 AM
Sponsors
|